# PUBLIC SUMMARY DOCUMENT

**Product:** Mediplast Australia Pty Ltd Wellspect HealthCare lleostomy/Koch

**Applicant:** Mediplast Australia Pty Ltd

**Date of SPAP Meeting:** 12 October 2021

## Proposed Deletion on the Stoma Appliance Scheme

The applicant, Mediplast Australia Pty Ltd, sought the deletion of the entire product range of Mediplast Australia Pty Ltd Wellspect HealthCare lleostomy/Koch (SAS Code 9822Y) in subgroup 8(c) of the Stoma Appliance Scheme (the Scheme) Schedule, due to the product no longer being manufactured. The product is currently listed at a unit price of $7.25, with a maximum monthly quantity of two units.

## Substitute products

Not Applicable.

**Variant to be deleted**

| **Product Code** | **Description** |
| --- | --- |
| 68730 | Non sterile catheter for continent ileostomy & koch pouch patients.  |

## Background

This product was first listed on the Scheme Schedule on 1 April 2011.

## Clinical Place for the Product

Not Applicable.

### Financial Analysis

The deletion of the entire product range is recommended. It is therefore, unlikely that there would be any budgetary impact for the Scheme as a consequence of deleting this product.

## Panel Recommendation

The Panel recommended the deletion of the entire product range of Mediplast Australia Pty Ltd Wellspect HealthCare lleostomy/Koch (SAS Code 9822Y) in subgroup 8(c) of the Scheme Schedule at the unit price of $7.25, with a maximum monthly quantity of two units.

The Panel also noted that Mediplast Australia Pty Ltd is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletion. A period of approximately six months from the date of the Panel’s recommendation (12 October 2021) should be given to allow users of the product to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

## Context for Decision

The Panel helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context.
A Panel decision not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following a decision not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government.
All Panel recommendations are subject to Cabinet/Ministerial approval.

## Applicant’s Comment

Mediplast notes the SPAP’s recommendation.